Kruse, Thomas
Novo Nordisk (Denmark)
4 papers on CoChatORCID 0000-0002-5756-753X
Most cited papers
- Verified
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry
Diabetes Treatment and ManagementChemical Synthesis and Analysis
Cited by 1,105
- Verified
Development of Cagrilintide, a Long-Acting Amylin Analogue
Kruse, T., Hansen, J. L., Dahl, K., Schäffer, L., Sensfuss, U., Poulsen, C., Schlein, M., Hansen, A. M. K., Jeppesen, C. B., Dornonville de la Cour, C., et al. (2021) · Journal of Medicinal Chemistry
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 129
- Verified
Glucose-sensitive insulin with attenuation of hypoglycaemia
Hoeg-Jensen, T., Kruse, T., Brand, C. L., Sturis, J., Fledelius, C., Nielsen, P. K., Nishimura, E., Madsen, A. R., Lykke, L., Halskov, K. S., et al. (2024) · Nature
Diabetes Management and ResearchPancreatic function and diabetes
Cited by 65
- Verified
Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: translational difficulties and pitfalls
Simonsen, L., Lau, J., Kruse, T., Guo, T., McGuire, J., Jeppesen, J. F., Niss, K., Sauerberg, P., Raun, K., & Dornonville de la Cour, C. (2022) · PLOS ONE
Diabetes Treatment and ManagementPharmacology and Obesity Treatment
Cited by 36
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free